Takeda Oncology
Laura Gagnon is a seasoned professional in the oncology sector, currently serving as Director of Global Oncology Expanded Patient Access Programs at Takeda Oncology. Gagnon has held various leadership roles, including Associate Director positions focused on Global Evidence Generation and Cell Therapy, showcasing a robust background in expanded patient access and evidence generation for new launches. Prior experience includes clinical project management at Karyopharm Therapeutics Inc. and multiple roles at ECOG-ACRIN Cancer Research Group, contributing to cooperative group-sponsored trials. Gagnon started a career in staffing management with Kelly Services. Educational credentials include a Bachelor of Arts in Spanish and Public Relations from York College of Pennsylvania and a study abroad program in Spanish and Marine Biology from Universidad LCI Veritas.
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.